



Press Release  
November 18, 2010

## **Additional prolongation for subscription**

The Board of Directors of ChronTech Pharma AB has decided to further prolong the time for subscription for shares in the ongoing rights issue with another 26 days until the 15<sup>th</sup> of December 2010. This is the last and final prolongation of this issue. For subscription forms, terms and instructions see the Prospectus (only available in Swedish) on the company website, [www.chrontech.se](http://www.chrontech.se).

### **For more information, please contact:**

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB  
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28,  
E-mail: [anders.vahlne@ki.se](mailto:anders.vahlne@ki.se)

### **About ChronTech**

*ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic infections with jaundice causing viruses which can lead to liver cirrhosis and liver cancer. ChronTech has also developed and further develops a patent pending new type of injection needle for a more effective uptake of DNA vaccines. ChronTech also have part ownership in the wound healing therapy ChronSeal®, and in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium AB is Certified Adviser for ChronTech. For more information, please visit: [www.chrontech.se](http://www.chrontech.se)*

In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.